The FDA has approved bimekizumab-bkzx (Bimzelx, UCB Pharma) for the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS).
Bimekizumab-bkzx is the first approved treatment for these three indications designed to selectively inhibit two key cytokines driving inflammatory processes: interleukin (IL)-17A and IL-17F. It was approved for the treatment of